• $8.4M
    Market Cap
  • 0.92%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: N/A
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

No data found

No data found

Peers

Statistics

More
Day Range
$0.80
$0.80
$0.80
1-Year Range
$0.71
$0.96
$0.80
Latest Close$0.80
Change
-$0.04 (-4.43%)
Volume5,000
Market Cap$8.4M
Shares Outstanding10.4M
P/E (TTM)-1.18
Diluted EPS (TTM)-$0.68
Enterprise Value$4.6M

Information as of 06/02/2026

Company Profile

$8.4M
Market Cap
-$7.1M
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
2-1250 Waverley Street, Winnipeg, MB, Canada, R3T 6C6
204 487 7412

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Key Executives

  • Albert David Friesen
  • Neil Owens
  • Haaris Uddin
  • Reuben Saba

Current Ownership Distribution

  • Other10.4M (100.00%)
  • Institutions0 (0.00%)
  • Mutual Funds0 (0.00%)
  • Insiders0 (0.00%)